82 FR 12968 - Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee; Amendment of Notice
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Federal Register Volume 82, Issue 44 (March 8, 2017)
Food and Drug Administration
Federal Register Volume 82, Issue 44 (March 8, 2017)
| Page Range | 12968-12968 | |
| FR Document | 2017-04529 |
[Federal Register Volume 82, Number 44 (Wednesday, March 8, 2017)] [Notices] [Page 12968] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-04529] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2017-N-0067] Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee; Amendment of Notice AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of the joint meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee. This meeting was announced in the Federal Register of January 11, 2017. The amendment is being made to reflect a change in the ADDRESSES portion of the document. There are no other changes. FOR FURTHER INFORMATION CONTACT: Stephanie L. Begansky, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301- 796-9001, FAX: 301-847-8533, email: [email protected], or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). Please call the Information Line for up-to-date information on this meeting. SUPPLEMENTARY INFORMATION: In the Federal Register of January 11, 2017 (82 FR 3333), FDA announced that the joint meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee would be held on March 13-14, 2017. On page 3334, in the first column, under the ADDRESSES caption, the address of the meeting and the phone number in the first six lines is changed to read as follows: ADDRESSES: The meeting will be held at the Tommy Douglas Conference Center, 10000 New Hampshire Ave., Silver Spring, MD 20903. The conference center's telephone number is 240-645-4000. This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees. Dated: March 3, 2017. Janice M. Soreth, Associate Commissioner for Special Medical Programs. [FR Doc. 2017-04529 Filed 3-7-17; 8:45 am] BILLING CODE 4164-01-P
![12968 Federal Register / Vol. 82, No. 44 / Wednesday, March 8, 2017 / Notices
As a general matter, information This is a revision to the previously Households, Businesses, Organizations,
collections will not result in any new approved collection to reduce the and/or State, Local or Tribal
system of records containing privacy burden hours from 12,400 to 9,690 Government. There is no cost to
information and will not ask questions hours as a result of the previous usage respondents other than their time. The
of a sensitive nature, such as sexual and anticipated future usage of this estimated annualized burden hours for
behavior and attitudes, religious beliefs, Generic Information Collection. this data collection activity are 9,690.
and other matters that are commonly Respondents will be screened and
considered private. selected from Individuals and
ESTIMATED ANNUALIZED BURDEN HOURS
Annual
Number of Hours
Type of collection frequency Total hours
respondents per response
per response
Online surveys ................................................................................................. 10,500 1 30/60 5,250
Discussion Groups ........................................................................................... 280 1 2 560
Focus groups ................................................................................................... 640 1 2 1280
Web site/app usability testing .......................................................................... 2,000 1 30/60 1,000
Interviews ......................................................................................................... 800 1 2 1,600
Totals ........................................................................................................ 14,220 ........................ ........................ 9,690
Leroy A. Richardson, Advisory Committee Information Line, DEPARTMENT OF HEALTH AND
Chief, Information Collection Review Office, 1–800–741–8138 (301–443–0572 in the HUMAN SERVICES
Office of Scientific Integrity, Office of the Washington, DC area). Please call the
Associate Director for Science, Office of the Information Line for up-to-date Indian Health Service
Director, Centers for Disease Control and
Prevention.
information on this meeting.
Notice To Propose the Re-Designation
[FR Doc. 2017–04510 Filed 3–7–17; 8:45 am] SUPPLEMENTARY INFORMATION: In the of the Service Delivery Area for the
BILLING CODE 4163–18–P Federal Register of January 11, 2017 (82 Passamaquoddy Tribe at Indian
FR 3333), FDA announced that the joint Township
meeting of the Drug Safety and Risk
DEPARTMENT OF HEALTH AND AGENCY: Indian Health Service, HHS.
Management Advisory Committee and
HUMAN SERVICES the Anesthetic and Analgesic Drug ACTION: Notice.
Products Advisory Committee would be SUMMARY: This notice advises the public
Food and Drug Administration
held on March 13–14, 2017. On page that the Indian Health Service (IHS)
[Docket No. FDA–2017–N–0067] 3334, in the first column, under the proposes to expand the geographic
ADDRESSES caption, the address of the boundaries of the Purchased/Referred
Joint Meeting of the Drug Safety and meeting and the phone number in the Care (PRC) Service Delivery Area (SDA)
Risk Management Advisory Committee first six lines is changed to read as for the Passamaquoddy Tribe’s
and the Anesthetic and Analgesic Drug follows: reservation at Indian Township
Products Advisory Committee; (Passamaquoddy at Indian Township or
Amendment of Notice ADDRESSES: The meeting will be held at
Tribe) in Maine. This notice does not
the Tommy Douglas Conference Center,
AGENCY: Food and Drug Administration, propose to change or expand the PRC
10000 New Hampshire Ave., Silver SDA for the Tribe’s Pleasant Point
HHS. Spring, MD 20903. The conference
ACTION: Notice. reservation. This notice only relates to
center’s telephone number is 240–645– the expansion of the Tribe’s PRC SDA
4000. for the Indian Township reservation.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an This notice is issued under the DATES: Comments must be submitted
amendment to the notice of the joint Federal Advisory Committee Act (5 April 7, 2017.
meeting of the Drug Safety and Risk U.S.C. app. 2) and 21 CFR part 14, ADDRESSES: You may submit comments
Management Advisory Committee and relating to the advisory committees. in one of four ways detailed below.
the Anesthetic and Analgesic Drug Dated: March 3, 2017. However, we cannot accept comments
Products Advisory Committee. This by facsimile (FAX) transmission due to
Janice M. Soreth,
meeting was announced in the Federal staff and resource limitations. Please
Register of January 11, 2017. The Associate Commissioner for Special Medical
Programs.
choose one method below:
amendment is being made to reflect a 1. Electronically. You may submit
change in the ADDRESSES portion of the [FR Doc. 2017–04529 Filed 3–7–17; 8:45 am]
electronic comments on this regulation
document. There are no other changes. BILLING CODE 4164–01–P to http://www.regulations.gov. Follow
FOR FURTHER INFORMATION CONTACT: the ‘‘Submit a Comment’’ instructions.
mstockstill on DSK3G9T082PROD with NOTICES
Stephanie L. Begansky, Center for Drug 2. By regular mail. You may mail
Evaluation and Research, Food and written comments to the following
Drug Administration, 10903 New address ONLY: Betty Gould, Regulations
Hampshire Ave., Bldg. 31, Rm. 2417, Officer, Indian Health Service, 5600
Silver Spring, MD 20993–0002, 301– Fishers Lane, Mailstop: 09E70,
796–9001, FAX: 301–847–8533, email: Rockville, Maryland 20852. Please allow
AADPAC@fda.hhs.gov, or FDA sufficient time for mailed comments to
VerDate Sep<11>2014 17:34 Mar 07, 2017 Jkt 241001 PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 E:\FR\FM\08MRN1.SGM 08MRN1](https://thefederalregister.org/doc/82_FR_13012/page/1.svg)
Document Created: 2017-03-08 05:07:06
Document Modified: 2017-03-08 05:07:06
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Contact | Stephanie L. Begansky, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301- 796-9001, FAX: 301-847-8533, email: [email protected], or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). Please call the Information Line for up-to-date information on this meeting. | |
| FR Citation | 82 FR 12968 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR